El Jurdi, Najla http://orcid.org/0000-0002-9268-9655
Okoev, Grigori http://orcid.org/0000-0003-3439-4362
DeFor, Todd E. http://orcid.org/0000-0003-4667-0176
Holtan, Shernan G.
Betts, Brian C.
Blazar, Bruce R.
Brunstein, Claudio G. http://orcid.org/0000-0002-1997-3799
MacMillan, Margaret L. http://orcid.org/0000-0002-0755-0852
Weisdorf, Daniel J. http://orcid.org/0000-0001-8078-8579
Arora, Mukta http://orcid.org/0000-0001-9362-0556
Funding for this research was provided by:
SGH - consultant for Incyte, Bristol Meyers Squibb, and Generon.
Article History
Received: 9 September 2021
Revised: 11 February 2022
Accepted: 17 February 2022
First Online: 5 March 2022
Competing interests
: The authors declare the following competing interests, none of which is directly relevant to this work. BRB—receives remuneration as an advisor to Magenta Therapeutics and BlueRock Therapeutics; research funding from BlueRock Therapeutics, Rheos Medicines, Equilibre biopharmaceuticals, Carisma Therapeutics, Inc., and is a co-founder of Tmunity Therapeutics. SGH—consultant for Incyte, Bristol Meyers Squibb, and Generon. DJW—research support from Incyte.